These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35072719)

  • 1. Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy.
    Hellwig K; Tokic M; Thiel S; Esters N; Spicher C; Timmesfeld N; Ciplea AI; Gold R; Langer-Gould A
    JAMA Netw Open; 2022 Jan; 5(1):e2144750. PubMed ID: 35072719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy.
    Hellwig K; Tokic M; Thiel S; Hemat S; Timmesfeld N; Ciplea AI; Gold R; Langer-Gould AM
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37217309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis.
    Haben S; Ciplea AI; Tokic M; Timmesfeld N; Thiel S; Gold R; Langer-Gould AM; Hellwig K
    J Neurol Neurosurg Psychiatry; 2024 Jan; 95(2):151-157. PubMed ID: 37536925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
    Vukusic S; Durand-Dubief F; Benoit A; Marignier R; Frangoulis B; Confavreux C
    Mult Scler; 2015 Jun; 21(7):953-5. PubMed ID: 25305253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy.
    Thiel S; Litvin N; Haben S; Gold R; Hellwig K
    J Neurol Neurosurg Psychiatry; 2024 May; 95(6):561-570. PubMed ID: 38124108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
    Portaccio E; Moiola L; Martinelli V; Annovazzi P; Ghezzi A; Zaffaroni M; Lanzillo R; Brescia Morra V; Rinaldi F; Gallo P; Tortorella C; Paolicelli D; Pozzilli C; De Giglio L; Cavalla P; Cocco E; Marrosu MG; Solaro C; Uccelli A; Laroni A; Pastò L; Giannini M; Trojano M; Comi G; Amato MP;
    Neurology; 2018 Mar; 90(10):e832-e839. PubMed ID: 29438041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
    Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
    Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs.
    Portaccio E; Ghezzi A; Hakiki B; Sturchio A; Martinelli V; Moiola L; Patti F; Mancardi GL; Solaro C; Tola MR; Pozzilli C; De Giglio L; Totaro R; Lugaresi A; De Luca G; Paolicelli D; Marrosu MG; Comi G; Trojano M; Amato MP;
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):845-50. PubMed ID: 24403285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
    Berenguer-Ruiz L; Gimenez-Martinez J; Palazón-Bru A; Sempere AP
    J Neurol; 2019 Oct; 266(10):2512-2517. PubMed ID: 31256279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.
    Pastò L; Portaccio E; Ghezzi A; Hakiki B; Giannini M; Razzolini L; Piscolla E; De Giglio L; Pozzilli C; Paolicelli D; Trojano M; Marrosu MG; Patti F; La Mantia L; Mancardi GL; Solaro C; Totaro R; Tola MR; Di Tommaso V; Lugaresi A; Moiola L; Martinelli V; Comi G; Amato MP;
    BMC Neurol; 2012 Dec; 12():165. PubMed ID: 23276328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
    Bsteh G; Algrang L; Hegen H; Auer M; Wurth S; Di Pauli F; Deisenhammer F; Berger T
    Mult Scler; 2020 Jan; 26(1):69-78. PubMed ID: 30507345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis.
    Bove R; Applebee A; Bawden K; Fine C; Shah A; Avila RL; Belviso N; Branco F; Fong K; Lewin JB; Liu J; England SM; Vignos M
    Mult Scler Relat Disord; 2024 Aug; 88():105738. PubMed ID: 38959591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
    Demortiere S; Rico A; Maarouf A; Boutiere C; Pelletier J; Audoin B
    Mult Scler; 2021 Apr; 27(5):712-718. PubMed ID: 32202216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.
    Hughes J; Jokubaitis V; Lugaresi A; Hupperts R; Izquierdo G; Prat A; Girard M; Duquette P; Grand'Maison F; Grammond P; Sola P; Ferraro D; Ramo-Tello C; Trojano M; Slee M; Shaygannejad V; Boz C; Lechner-Scott J; Van Pesch V; Pucci E; Solaro C; Verheul F; Terzi M; Granella F; Spitaleri D; Alroughani R; Jun JK; Fambiatos A; Van der Walt A; Butzkueven H; Kalincik T;
    JAMA Neurol; 2018 Nov; 75(11):1407-1415. PubMed ID: 30083762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.
    Portaccio E; Pastò L; Razzolini L; Moiola L; Martinelli V; Annovazzi P; Ghezzi A; Zaffaroni M; Lanzillo R; Brescia Morra V; Rinaldi F; Gallo P; Gasperini C; Paolicelli D; Simone M; Pozzilli C; De Giglio L; Cavalla P; Cocco E; Marrosu MG; Patti F; Solaro C; Comi G; Filippi M; Trojano M; Amato MP
    Mult Scler; 2022 Nov; 28(13):2137-2141. PubMed ID: 35296189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies.
    Sahloul O; Louapre C; Beigneux Y; Lubetzki C; Maillart E; Roux T
    Mult Scler Relat Disord; 2024 May; 85():105557. PubMed ID: 38520946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses.
    Hellwig K; Rockhoff M; Herbstritt S; Borisow N; Haghikia A; Elias-Hamp B; Menck S; Gold R; Langer-Gould A
    JAMA Neurol; 2015 Oct; 72(10):1132-8. PubMed ID: 26322399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.